Every round on record, with the sources behind each and the investors on them.
A leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives
souffletx.comBoston, MABiotech
4 sources
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The roundup attributes the financing to Soufflé’s official LinkedIn post but names no round investors; Polaris Partners is mentioned in connection with company leadership, not as a financing lead.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $135M | 2026-10-13 | Juvia Group | 3 outlets. #34 in Trending |
4 sources [ VERIFIED · CORRECTED ] read against 3 of 4 sources | ||||
Soufflé Therapeutics develops cell-specific oligonucleotide and siRNA medicines that deliver genetic therapies into disease-causing cells, initially targeting muscle, heart and metabolic disorders.
Soufflé is tackling the longstanding problem of delivering RNA medicines beyond the liver into the specific cells and tissues that drive disease, beginning with skeletal muscle and heart cells in conditions with limited treatment options. Its oversubscribed $135 million Series B is intended to fund first clinical studies in facioscapulohumeral muscular dystrophy, heart failure and muscle and metabolic disorders while advancing the company’s cell-specific REMEDY delivery platform.
Checked against 10 sources today
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-10-07 | not stated | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources The roundup attributes the financing to Soufflé’s official LinkedIn post but names no round investors; Polaris Partners is mentioned in connection with company leadership, not as a financing lead. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: fiercebiotech.com, pharmaphorum.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: a Leading Sovereign Wealth Fund